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Abstract Coronary artery disease (CAD) is believed to
be the single leading cause of death in both men and
women in the world. Smoking is the most important risk
factor for CAD. Smoking increases platelet aggregation
and thrombus formation. CD40 ligand (CD40L) is a
transmembrane glycoprotein derived from activated plate-
lets. It participates in thrombus formation during the acute
phase of acute myocardial infarction (MI). Elevation of
CD40L identiﬁes the patients who are at highest risk for
cardiac events and who are likely to beneﬁt from treatment
with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antag-
onists. The purpose of this study was to evaluate levels of
CD40L in smokers with acute MI. Fifty-seven patients with
acute MI were enrolled in this study. Thirty-one smokers
were compared with 26 non-smokers. Soluble CD40L level
in the plasma was determined by a standard enzyme-linked
immunosorbent assay. Circulating levels of CD40L were
higher in the smokers’ group. Smokers with acute MI may
have increased risk for thrombotic complications during
acute MI, and optimal antiaggregant therapy should be
administered.
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Introduction
Cigarette smoking is accepted as one of the major factors
that increase the risk of coronary artery disease (CAD) and
heart attacks. Smokers have a three to four times higher
risk of developing a heart attack compared with non-
smokers [1]. A large number of young people suffering
from myocardial infarction (MI) are smokers [2]. There are
several ways in which tobacco can inﬂuence the cardio-
vascular system. Smoking accelerates atherosclerosis
through damage to the endothelium and is associated with
proinﬂammatory and prothrombotic responses. Post-mor-
tem studies have provided evidence of accelerated ath-
erogenesis in asymptomatic smokers [3]. Tobacco smoke
also increases the blood coagulability contributing to MI.
In vivo platelet activation occurs immediately after
smoking a cigarette [4]. Smoking-induced platelet activa-
tion can be a signiﬁcant contributory mechanism for acute
coronary events in smokers.
CD40 and its ligand (CD40L) are glycoproteins from the
tumor necrosis factor family [5]. Ligation of CD40 on
various vascular cells contributes to the pathogenesis of
atherosclerotic, thrombotic, and inﬂammatory processes [6,
7]. Soluble CD40L is shed from platelets upon platelet
activation and triggers monocyte activation [8]. The pivotal
role of platelet activation in atherothrombosis has made
CD40L an interesting subject in the setting of cardiovas-
cular disease and of acute MI. The rapid closure of the
coronary artery by acutely formed arterial thrombi, which
are composed of platelets, ﬁbrin, and inﬂammatory cells, is
the major cause of acute myocardial infarction [9].
Inﬂammatory markers like high-sensitivity C-reactive
protein (CRP), human tumor necrosis factor a, and inter-
leukin 6 are elevated in acute coronary syndromes [10].
CD40L levels are also elevated in patients with acute MI
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DOI 10.1007/s00380-010-0036-x[11]. In addition, several studies demonstrated that the
circulating level of CD40L was related to a high thrombus
burden in acute MI and long-term mortality [12–14].
Cigarette smokers also have upregulation of the CD40/
CD40L dyad [15]. However, there is no report about cir-
culating levels of CD40L in smokers with acute MI. The
aim of this study is to examine CD40L levels in smoker
patients with acute MI versus non-smokers.
Materials and methods
Patient population
A total of 57 patients with ST-segment elevation AMI were
enrolled in this study. Thirty-one smokers (group 1) were
compared with 26 non-smokers (group 2). Smokers were
deﬁned as those currently smoking any type of tobacco in
more than ten cigarettes per day and ex-smoker patients
were excluded from the study. All patients provided
informed consent for participating in the study. The study
protocol was approved by the local ethics committee.
Exclusion criteria were diabetes mellitus, atrial ﬁbrilla-
tion, renal or hepatic failure, signiﬁcant valvular abnor-
malities, chronic obstructive pulmonary disease, active
inﬂammatory or connective tissue diseases, malignancy,
febrile disorders, cardiogenic shock patients requiring
intraaortic balloon pump therapy, patients with a history of
recent surgery or trauma within the preceding 2 months
and those with acute MI onset [24 h, or age C85 years.
Patients were excluded if antiplatelet agents such as ace-
tylsalicylic acid and clopidogrel had been used for any
medical reason. Also, the patients that were given these
agents and heparin during transfer to the hospital were
excluded. None of the patients had a history of CAD,
percutaneous coronary intervention (PCI), or coronary
artery bypass graft surgery. Acute MI was deﬁned as typ-
ical chest pain lasting for more than 30 min with ST-seg-
ment elevation [1 mm in two or more consecutive
precordial or extremity derivations.
Study protocol
Patients who were undergoing primary PCI were included
in the study. All patients were treated with clopidogrel
(loading 600 mg PO before PCI and followed with 75 mg
daily), enoxaparin (0.1 mg/kg SC), and a glycoprotein IIb/IIIa
(GPIIb/IIIa) receptor antagonist (tiroﬁban; loading 20 lg/kg
then 0.15 20 lg/kg/min infusion followed for 24 h). In the
emergency room during admission, PO 300 mg acetylsal-
icylic acid was given. Blood samples were taken at hospital
admission before the medical treatment with aspirin,
clopidogrel, glycoprotein inhibitors, and PCI. Thrombolysis
in the myocardial infarction (TIMI) ﬂow [16] and TIMI
frame count [17] of the infarct-related artery (IRA) were
measured before and after the procedure. The severity of
CAD was assessed by using the Gensini score [18].
Blood sampling and laboratory measurements
sCD40L levels were measured in plasma. Ethylenediami-
netetraacetic acid (EDTA) was used as anticoagulant. All
samples were stored at -80C until assayed. The concen-
tration of soluble CD40L levels in plasma was determined
by using a speciﬁc enzyme-linked immunosorbent assay
(ELISA) kit (Bender MedSystems GmbH Vienna, Austria).
Each serum sample was diluted 1:2 with sample diluent
into the each well. The interassay coefﬁcient of variation
(CV) was 6.8%, the intra-assay CV was 4.0%, and the
imprecision of the assay was\10%. All tests were done in
duplicate. Blood samples for detecting the peak creatinine
kinase-myocardial band (CK-MB) and troponin I values
were taken every 8 h during the ﬁrst 3 days after admis-
sion. The serum CK-MB levels were measured by an
Olympus AU 600 autoanalyzer (Olympus Optical Co.,
Ltd., Schimatsu-Mishima, Japan). Troponin I was analyzed
using a commercially available method (IMMULITE
Troponin I, Diagnostic Products Corp., Los Angeles, CA).
This is an immunometric method where antibodies raised
against human cTnI bind to existing cTnI in the sample.
C-reactive protein was measured by a nephelometry
method.
Statistical analysis
The statistical analysis was performed with the help of the
Statistical Package for Social Sciences (SPSS for Windows)
software(version11.0)(SPSSInc.,Chicago,IL).Differences
in prevalence were tested with the nonparametric chi-square
test. Unpaired t tests were used for between-two-group
comparisons. Also, the Mann-Whitney U test was used for
non-parametric comparison of two groups. A Spearmann
correlation test was used to assess linear association.
Variables were expressed as mean ± standard deviation, and
p values\0.05 were considered statistically signiﬁcant.
Results
In our study, the sample consisted of 57 patients. Patients
were subdivided into two groups according to their
smoking status. The circulating levels of soluble CD40L
were higher in smokers than in non-smokers, but the dif-
ference was in the range of assay imprecision (6.14 vs.
5.07 ng/ml, p = 0.01) (Fig. 1). Smokers were 10 years
younger than non-smokers (p = 0.001), and smoking was
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123more common in males (p = 0.001) (Table 1). There were
no signiﬁcant differences between groups for other bio-
chemical ﬁndings such as peak CK-MB, troponin I, cre-
atinine and ﬁbrinogen levels, WBC, and platelet counts.
The patients were divided into four groups to quartiles
of CD40L level. Gensini scores of each CD40L quartile
were similar (p = 0.4) (Fig. 2). Also, there was no corre-
lation between the levels of CD40L and the Gensini score
(r = 0.46, p = 0.3).
Angiographic ﬁndings, such as infarct location (anterior,
non-anterior), IRA, Gensini scores, and TIMI ﬂow were
similar in both groups (Table 2). Also, times from
symptom onset to reperfusion therapy were similar. The
TIMI frame count after the reperfusion procedure was
similar in each group (p = 0.16).
The plasma levels of sCD40L were analyzed for corre-
lation among demographic, laboratory, and angiographic
parameters (Table 3). There was no correlation between
plasma sCD40L levels and other parameters such as age,
Gensini score, peak CK-MB, and troponin levels, etc.
Discussion
In this study, sCD40L levels were evaluated in patients
undergoing primary PCI for acute MI. The circulating
levels of sCD40L were elevated in both smokers and non-
smokers during the early phase of acute MI. In spite of
higher CD40L levels, the post-procedural TIMI ﬂow was
similar in each group. GPIIb/IIIa receptor antagonist
administration after PCI to all patients could be a possible
explanation for improved coronary ﬂow inspite of high
sCD40L levels.
Smoking has been identiﬁed as a major risk factor for
CAD. A complex relationship exists between cigarette
smoking, haemostatic factors, and cardiovascular disease.
Celermajer et al. [19] found a marked reduction in both
ﬂow-mediated, endothelium-dependent and nitroglycerin-
induced, endothelium-independent vasodilatation of the
forearm arteries in long-term smokers. After disruption of
the endothelial layer, blood coagulation starts by platelet
activation and interaction of activated platelets. Platelets
also increased their activation as a response to cigarette
Fig. 1 CD40L levels of patients
Table 1 Baseline characteristics of patients in both groups
Smokers
(group 1)
(n = 31)
Non-smokers
(group 2)
(n = 26)
p
Age (years) 53.0 ± 8.8 62.7 ± 10.6 0.001
Male gender 28 16 0.001
Body mass index (kg/m
2) 25.8 ± 3.1 27.1 ± 4.8 0.3
Hypertension (%) 22 47 0.2
LDL-cholesterol (mg/dl) 124.5 ± 32.7 121.0 ± 29.4 0.7
Creatinine (mg/dl) 0.9 ± 0.3 0.9 ± 0.2 0.5
WBC count (910
3/ml) 12.9 ± 4.2 11.8 ± 4.2 0.3
Platelet counts (910
4/ml) 226.1 ± 47.3 220.0 ± 44.2 0.5
Peak CK-MB (IU/l) 217.9 ± 129.7 167.1 ± 101.8 0.2
Peak troponin I (ng/ml) 87.0 ± 61.9 73.3 ± 57.3 0.4
Fibrinogen (mg/dl) 329.5 ± 123.1 328.0 ± 52.4 0.9
CD40L (ng/ml) 6.1 ± 1.5 5.1 ± 1.8 0.01
WBC white blood cell, LDL low density lipoprotein, CK-MB creatine
kinase myocardial band, CD40L CD40 ligand
Fig. 2 Association between CD40L levels and Gensini scores
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123smoke. Soluble CD40L is released from activated platelets.
Harding et al. [15] demonstrated that the expression of
CD40L on platelets and platelet-monocyte aggregates
signiﬁcantly increased in healthy smokers compared to
non-smokers.
There have been contradictory results about the relation
between sCD40L levels and atherosclerosis risk factors. In
a large multiethnic population-based study, no association
was observed between quartiles of sCD40L and age, sex,
race, body mass index, diabetes, cholesterol levels, and
CRP [20]. In the Framingham Study participants, as
opposed to never smokers, those with acute cigarette
smoke exposure had signiﬁcantly lower concentrations of
plasma CD40L [21]. In this study, patients in the smoking
group were younger and more likely to be male, but age
and sex did not affect circulating CD40L levels.
There are limited data about the levels of CD40L during
acute coronary syndromes (ACS). Aukrust et al. [22]
showed that patients with stable and unstable angina had
elevated levels of CD40L compared with controls; partic-
ularly high levels occurred in patients with unstable dis-
ease. In addition, Heeschen et al. [11] demonstrated that
the levels of CD40L were signiﬁcantly higher in patients
with ACS (62% of the patients with ST-segment elevation
MI) than in patients with stable angina and patients without
heart disease. Except these reports, sufﬁcient data are not
available concerning the sCD40L levels in acute ST seg-
ment elevation MI. Youssef et al. [14] recently studied the
relation between the circulating level of sCD40L and
thrombus burden in the infarct-related artery. In the acute
phase of MI, sCD40L levels were signiﬁcantly higher in
the high thrombus formation group compared to the low
thrombus formation group. In the subgroup analysis of the
OPUS-TIMI 16 trial, Varo et al. [23] found that elevated
plasma levels of sCD40L ([0.52 ng/ml) identify the
patients with acute coronary syndromes at heightened risk
of death and recurrent MI independent of troponin-I and
CRP. The authors noted that the elevated levels of CD40L
not only play a central role in the pathogenesis of athero-
sclerosis and CAD, but also help to identify the patients at
high risk for ischemic events during acute coronary syn-
dromes. The predictive value of serum sCD40L levels was
investigated in patients with acute coronary syndromes
who were enrolled in the CAPTURE study [11]. The
sCD40L levels were elevated (above 5.0 lg/l) in 221
patients (40.6%). Elevated sCD40L levels were associated
with death and non-fatal MI during 6 months of follow-up.
The increased risk in patients with elevated sCD40L levels
was signiﬁcantly reduced by treatment with abciximab.
Similarly, smokers had higher sCD40L levels in this study
(6.14 vs. 5.07 ng/ml; the difference was in the range of
assay imprecision). This could be explained with more
thrombogenic, less atherogenic composition of the infarct
Table 2 Angiographic characteristics
Smoker (group 1) (n = 31) Non-smoker (group 2) (n = 26) p
Anterior wall MI 24 23 0.17
Infarct-releated artery (LAD/Cx/RCA) 24/3/4 23/0/3 0.25
Gensini score 76 (IQR: 48) 108 (IQR: 97.5) 0.20
Time from symptom onset to reperfusion therapy (h) 3.5 (IQR: 2) 4.5 (IQR: 2.5) 0.28
Pre-PCI TIMI ﬂow 0 (IQR: 0.5) 0 (IQR: 0.25) 0.67
Post-PCI TIMI ﬂow 3 (IQR: 1) 3 (IQR: 0.5) 0.28
TIMI frame count after the procedure 16.5 (IQR: 8.75) 22.0 (IQR: 11.5) 0.14
IQR interquartile range, MI myocardial infarction, LAD left anterior descending artery, Cx circumfrex coronary artery, RCA right coronary artery,
PCI percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction
Table 3 Correlation between sCD40L levels and demographic fea-
tures, laboratory ﬁndings, and angiographic characteristics
Variables sCD40L
Correlation
coefﬁcient (r)
p
Age 0.03
a 0.79
BMI 0.10
a 0.47
Creatinine 0.06
a 0.60
WBC -0.03
a 0.79
Peak CK-MB 0.11
a 0.36
Peak troponin I 0.14
a 0.30
Time from symptom onset
to reperfusion therapy
0.18
b 0.17
Pre-PCI TMI frame count -0.06
b 0.64
Post-PCI TIMI frame count -0.07
b 0.61
Gensini score -0.15
b 0.28
BMI body mass index, WBC white blood cell, CK-MB creatine kinase
myocardial band, PCI percutaneous coronary intervention, TIMI
thrombolysis in myocardial infarction
a Correlation coefﬁcient was obtained with Pearson correlation
analysis
b Correlation coefﬁcient was obtained with Spearman’s correlation
analysis
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123lesion in smokers [24]. Smoking enhances platelet aggre-
gation and then thrombus formation [25]. Soluble CD40L
released from platelets upon activation indicates the
hypercoagulable state promoting vascular thrombosis in
active smokers.
Two studies were found in the literature search [26, 27]
in which CD40L failed to predict the prognosis after acute
MI. Tan et al. [26] reported that elevated levels of CD40L
had no prognostic value for patients with ST segment
elevation MI in 2 years of follow-up. The result of this
study is controversial because for cardiovascular morbid-
ity, including re-MI, rehospitalization for acute coronary
syndromes were not evaluated during the follow-up period.
Secondly, Morrow et al. [27] detected that sCD40L was not
associated with a risk of non-fatal recurrent ischemic
events in patients with non-ST elevation acute coronary
syndromes. The authors have discussed that the uniform
treatment of patients in this study with a platelet GPIIb/IIIa
receptor antagonist had an impact on the strength of the
relationship. This argument is supported by the results of
the present study.
Elevation of sCD40L identiﬁes the patients who are at
highest risk for cardiac events [11]. Recently, many studies
have shown that GPIIb/IIIa receptor antagonists are capa-
ble of inhibiting the release of sCD40L in a dose-dependent
manner [27–29]. We hypothesized that smokers with acute
ST elevation MI who undergo primary angioplasty could
beneﬁt from GPIIb/IIIa inhibitor use to a greater extent
than non-smokers, but there are conﬂicting data about the
beneﬁts of glycoprotein IIb/IIIa (GPIIb/IIIa) receptor
antagonist treatment in smoking patients with acute MI and
elevated sCD40L levels [11, 30, 31]. In the CAPTURE
study including patients with acute coronary syndromes,
the increased risk in both smoker and non-smoker patients
with elevated sCD40L levels was signiﬁcantly reduced by
treatment with abciximab [11]. Hasdai et al. [30] evaluated
the effect of eptiﬁbatide, a GPIIb/IIIa receptor antagonist,
in smokers with acute non-ST elevation MI in the PUR-
SUIT trial. Eptiﬁbatide did not result in more improvement
in smokers’ outcomes compared with nonsmokers. Weisz
et al. [31] examined the impact of smoking on patients
undergoing primary PCI for AMI in the CADILLAC trial.
Abciximab was not associated with better outcome in
smokers. Taken together, a greater beneﬁt of GPIIb/IIIa
receptor blocker therapy in smoking acute MI patients
compared with non-smokers is still controversial and needs
to be addressed in larger studies.
In one study, Lee et al. [32] examined the relation
between higher CD40L levels and Gensini score in patients
with stable angina requiring interventional treatment. Ele-
vated sCD40L levels and CAD severity calculated with
Gensini scores were more common in patients with meta-
bolic syndrome. We did not ﬁnd any difference among the
sCD40L quartiles for the Gensini score, and there was no
correlation between the sCD40L levels and the Gensini
score. The association between elevated sCD40L levels and
CAD severity has not been mentioned before in acute MI.
This score is accepted as a marker of severity of CAD in
stablepatients.SeverityoftheGensiniscoresissubstantially
inﬂuencedbythedegreeandlocationofobstruction.Gensini
scores of stable patients may be suddenly increased in acute
MI because total occlusion due to thrombus formation was
frequentlyseeninangiographicrecordsofpatientwithacute
MI.Inaddition,itiswellknownthatsCD40Lplaysapivotal
role in thrombus formation, but the relationship between
sCD40L levels and localization of the thrombotic lesion site
is not clear. In summary, we did not detect any association
between sCD40L levels and Gensini score. Despite
increased sCD40L levels in smokers, Gensini scores were
similar in both groups.
Study limitations
This study is a pilot study raising a hypothesis that must be
conﬁrmed in larger studies. The main limitation of this
study is the small sample size. Because of this limitation,
multivariate regression analysis was not performed to
detect the independent predictors of the sCD40L level, and
also an independent association between smoking status
and plasma sCD40L level was not interpreted. Results
could be strengthened with additional evidence conﬁrming
activation of the sCD40L pathway. Another limitation of
the study is the lack of healthy subjects as a control group.
The results of this study cannot be generalized to late-term
revascularized patients. Additionally, this is a cross-sec-
tional study, and therefore, the importance of the results
should be assessed by clinic follow-up studies. We studied
the patients undergoing primary PCI, and all patients
received tiroﬁban, enoxaparine, clopidogrel, and acetyl-
salicylic acid. Hence, the present study does not answer the
question of whether smokers with acute MI were at a
disadvantage with the therapy not including GPIIb/IIIa
receptor antagonists.
Conclusion
Despite these limitations, this study demonstrated that
circulating levels of sCD40L are increased in smokers
during the early phase of acute MI. Therefore, smokers
with acute MI may have an increased risk of thrombotic
complications during acute MI. Optimal antiaggregant
therapy including GPIIb/IIIa receptor antagonists should be
administered to patients smoking cigarettes during the
acute MI setting.
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